Business Description
Veracyte Inc
NAICS : 541380
SIC : 8734
ISIN : US92337F1075
Description
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.92 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.68 | |||||
| Interest Coverage | 2749.25 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 20.53 | |||||
| Beneish M-Score | -2.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 31.1 | |||||
| 3-Year EBITDA Growth Rate | -10.6 | |||||
| 3-Year EPS without NRI Growth Rate | 44 | |||||
| 3-Year Book Growth Rate | 25.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.91 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.93 | |||||
| 9-Day RSI | 66.95 | |||||
| 14-Day RSI | 66.5 | |||||
| 3-1 Month Momentum % | 25.71 | |||||
| 6-1 Month Momentum % | 73.27 | |||||
| 12-1 Month Momentum % | 49.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.08 | |||||
| Quick Ratio | 4.79 | |||||
| Cash Ratio | 3.9 | |||||
| Days Inventory | 54.83 | |||||
| Days Sales Outstanding | 38.69 | |||||
| Days Payable | 36.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8 | |||||
| Shareholder Yield % | -0.07 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.84 | |||||
| Operating Margin % | 2.59 | |||||
| Net Margin % | -2.18 | |||||
| FCF Margin % | 13.28 | |||||
| ROE % | -0.84 | |||||
| ROA % | -0.78 | |||||
| ROIC % | 1.33 | |||||
| 3-Year ROIIC % | 2.46 | |||||
| ROC (Joel Greenblatt) % | -15.05 | |||||
| ROCE % | -0.73 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 88.1 | |||||
| PE Ratio without NRI | 69.84 | |||||
| PS Ratio | 7.77 | |||||
| PB Ratio | 2.87 | |||||
| Price-to-Tangible-Book | 11.05 | |||||
| Price-to-Free-Cash-Flow | 59.52 | |||||
| Price-to-Operating-Cash-Flow | 50.71 | |||||
| EV-to-EBIT | -381.73 | |||||
| EV-to-Forward-EBIT | 33.45 | |||||
| EV-to-EBITDA | 107.96 | |||||
| EV-to-Forward-EBITDA | 30.38 | |||||
| EV-to-Revenue | 7.33 | |||||
| EV-to-Forward-Revenue | 6.41 | |||||
| EV-to-FCF | 55.2 | |||||
| Price-to-GF-Value | 1.38 | |||||
| Price-to-Projected-FCF | 3.55 | |||||
| Price-to-Median-PS-Value | 1.45 | |||||
| Price-to-Graham-Number | 5.98 | |||||
| Price-to-Net-Current-Asset-Value | 13.33 | |||||
| Price-to-Net-Cash | 19.65 | |||||
| Earnings Yield (Greenblatt) % | -0.27 | |||||
| FCF Yield % | 1.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VCYT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Veracyte Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 425.331 | ||
| EPS (TTM) ($) | -0.15 | ||
| Beta | 2.17 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.37 | ||
| Volatility % | 46.63 | ||
| 14-Day RSI | 66.5 | ||
| 14-Day ATR ($) | 1.791302 | ||
| 20-Day SMA ($) | 41.442 | ||
| 12-1 Month Momentum % | 49.61 | ||
| 52-Week Range ($) | 18.61 - 46 | ||
| Shares Outstanding (Mil) | 77.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Veracyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Veracyte Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Veracyte Inc Frequently Asked Questions
What is Veracyte Inc(VCYT)'s stock price today?
The current price of VCYT is $44.40. The 52 week high of VCYT is $46.00 and 52 week low is $18.61.
When is next earnings date of Veracyte Inc(VCYT)?
The next earnings date of Veracyte Inc(VCYT) is 2025-02-21 Est..
Does Veracyte Inc(VCYT) pay dividends? If so, how much?
Veracyte Inc(VCYT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers